Clinical Predicting Factors of Adefovir Dipivoxil Therapy in Patients with Chronic Hepatitis B.
10.11969/j.issn.1673-548X.2017.06.017
- VernacularTitle:影响阿德福韦酯治疗慢性乙型肝炎疗效的临床因素分析
- Author:
Haibin YU
;
Huiguo DING
- Keywords:
Chronic hepatitis B;
Adefovir dipivoxil;
Prediction
- From:
Journal of Medical Research
2017;46(6):63-67
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and the predictive factors of adefovir dipivoxil (ADV) therapy in patients with chronic hepatitis B(CHB).Methods Fifty two CHB patients were recruited in this study.All patients were treated for 52 weeks.Liver function,blood cell amounts and HBV DNA levels were detected at time course.Results At time point of 4 weeks,the serum HBV DNA level in good response group were significantly less than poor response group (2.48 ± 0.45 log10 vs 4.72 ± 0.28 log10,P ＜ 0.05).The decreased log value of HBV DNA in good response group was significantly higher than poor response group (3.31 ± 0.36 vs 1.54 ± 0.44,P ＜0.05).At time point of 12 weeks,the decreased log value of HBV DNA and neutrophil percent in good response group were significantly higher than poor response group [3.31 ± 0.36 vs 1.54 ± 0.44,(58.38 ± 2.08) × 109/L vs (46.90 ± 3.01) × 109/L,P ＜ 0.05],the serum HBV DNA level and red blood cell level in good response group were significantly less than poor response group[0.80 ± 0.27 log10vs4.63 ±0.43 log10,(4.50±0.08) ×1012/L vs (6.01 ±0.13) × 1012/L,P ＜0.05].Conclusion The decreased log value of HBV DNA and red blood cell level of 12weeks are the independently predictive factors for adefovir dipivoxil (ADV) therapy in patients with chronic hepatitis B.
